BRISBANE, Calif., Dec. 12, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that it has provided an unrestricted grant to the HeartBrothers Foundation based in Framingham, MA to continue patient support and education for heart transplant recipients in several New England states in 2015.
The HeartBrothers Foundation is a 501c(3) organization with the mission of bringing resources together to help patients and their loved ones effectively deal with the challenges of living with heart failure. Programs include organ donation awareness, transportation to medical appointments and patient education programs such as living with heart failure and life post-organ transplant. The services that the Foundation provides include lodging, meals for patients and their families and a support blog.
"This grant from CareDx will assist us in preparing for multiple meetings and symposiums at several centers across New England next year," said Pat Sullivan, one of the organization's founders and a survivor of heart failure. "Together we can build awareness and educate both medical professionals and patients along with their care giving loved ones."
"As part of our commitment to improving the lives of transplant patients in the U.S., we are very proud to support a worthwhile organization such as the HeartBrothers Foundation. They have established a solid community that provides valuable assistance to heart failure patients as they transition through their stages of care," said Peter Maag, President and CEO of CareDx.
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. For more information, please visit: www.CareDxInc.com.